Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 181

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Muscle myostatin signalling is enhanced in experimental cancer cachexia

Costelli, P., Muscaritoli, M., Bonetto, A., Penna, F., Reffo, P., Bossola, M., Bonelli, G., Doglietto, G. B., Baccino, F. M., Fanelli, F. Rossi · 2008 · European Journal of Clinical Investigation

Abstract

Background/Aims Myostatin belongs to the transforming growth factor‐β superfamily and negatively regulates skeletal muscle mass. Its deletion induces muscle overgrowth, while, on the contrary, its overexpression or systemic administration cause muscle atrophy. The present study was aimed at investigating whether muscle depletion as occurring in an experimental model of cancer cachexia, the rat bearing the Yoshida AH‐130 hepatoma, is associated with modulations of myostatin signalling and whether the cytokine tumour necrosis factor‐α may be relevant in this regard. Materials and methods Protein levels of myostatin, follistatin (myostatin endogenous inhibitor) and the activin receptor type IIB have been evaluated in the gastrocnemius of tumour‐bearing rats by Western blotting. Circulating myostatin and follistatin in tumour hosts were evaluated by immunoprecipitation, while the DNA‐binding activity of the SMAD transcription factors was determined by electrophoretic‐mobility shift assay. Results In day 4 tumour hosts muscle myostatin levels were comparable to controls, yet follistatin was reduced, and SMAD DNA‐binding activity was enhanced. At day 7, both myostatin and follistatin increased in tumour bearers, while SMAD DNA‐binding activity was unchanged. To investigate whether tumour necrosis factor‐α contributed to induce such changes, rats were administered pentoxifylline, an inhibitor of tumour necrosis factor‐α synthesis that partially corrects muscle depletion in tumour‐bearing rats. The drug reduced both myostatin expression and SMAD DNA‐binding activity in day 4 tumour hosts and up‐regulated follistatin at day 7. Conclusions These observations suggest that myostatin pathway should be regarded as a potential therapeutic target in cancer cachexia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2362.2008.01970.x

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 181

Metadata

Authors
Costelli, P., Muscaritoli, M., Bonetto, A., Penna, F., Reffo, P., Bossola, M., Bonelli, G., Doglietto, G. B., Baccino, F. M., & Fanelli, F. R.
Venue
European Journal of Clinical Investigation
Publisher
Wiley
Published
2008-06-28
Volume
38
Issue
7
Pages
531-538
ISSN
  • 0014-2972 (ISSN-L)
  • 1365-2362
OpenAlex
W2156180119
Cited by
181
References
12
FWCI
5.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Muscle myostatin signalling is enhanced in experimental cancer cachexia. https://app.cochat.ai/papers/10.1111/j.1365-2362.2008.01970.x
The paper
Costelli, P., Muscaritoli, M., Bonetto, A., Penna, F., Reffo, P., Bossola, M., Bonelli, G., Doglietto, G. B., Baccino, F. M., & Fanelli, F. R. (2008). Muscle myostatin signalling is enhanced in experimental cancer cachexia. European Journal of Clinical Investigation. https://doi.org/10.1111/j.1365-2362.2008.01970.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.